New research suggests that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt traditional lifestyle regimens.
Research printed in a prominent medical journal shows that while obese people frequently drop about a fifth of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using these medications must be cognizant of the potential of rapid rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to original mass in about one and a half years.
Weighing Approaches
The study, which examined 37 of trials involving thousands of patients, compared the outcomes of the injectable medications with other pills.
Scientists point out that people who lose weight through diet and exercise usually have a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors suggest the way of the jabs explains the heightened weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making overeating far more likely."
An Ongoing Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of weight regain, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
Patient Testimonies
People who have discontinued the medication describe a intense resurgence of cravings.
"I experienced something that goes on and you become starving," described one woman.
This challenge is compounded if users have not developed permanent dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while the jabs are effective agents for weight loss, they are not a standalone cure and lasting health benefits relies on combined behavioural support.
